Buy Stocks Easy | About Us
January 26, 2022
Buy Stocks Easy | Online Stocks

MRSN


Buy Mersana Therapeutics, Inc. Stock (symbol: MRSN) Easy Online

Company Name: Mersana Therapeutics, Inc.

Symbol: MRSN

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2017

MRSN Current Share Price

Today's MRSN ( Mersana Therapeutics, Inc. ) opening price: $

Yesterday's MRSN ( Mersana Therapeutics, Inc. ) closing price: $

Mersana Therapeutics, Inc. Stock ( symbol: MRSN ) Price Chart since IPO (2017):

12 Months Mersana Therapeutics, Inc. Stock ( symbol: MRSN ) Price Chart

Popular Questions about Mersana Therapeutics, Inc. Public Stock ( MRSN )

A: Mersana Therapeutics, Inc. stock symbol (also called stock or share ticker) is MRSN

A: Mersana Therapeutics, Inc. IPO (Initial Public Offering) took place on 2017

A: Mersana Therapeutics, Inc.'s stock (MRSN symbol) price at ther IPO (initial Public Offering) was $

Q: Is MRSN stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Mersana Therapeutics, Inc. stock (symbol: MRSN) at the beginning of 2019, at the opening share price of $4.5800, with a minimum of $200, by now your shares would be worth $8932 and your profit would be $8732 - SHOW ONLY IF PROFIT.

Buy Mersana Therapeutics, Inc. Stock Easy Online

Mersana Therapeutics, Inc. Stock Ticker Price Chart since IPO:





Mersana Therapeutics, Inc. Stock Price Yesterday



 


Mersana Therapeutics, Inc. Stock Price – Last Week




 


Mersana Therapeutics, Inc. Stock Price – Last Month




 


Mersana Therapeutics, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            https://seekingalpha.com/article/4305141-mersana-therapeutics-inc-mrsn-ceo-anna-protopapas-q3-2019-results-earnings-call-transcript
                            

                                
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q3 2019 Results - Earnings Call Transcript

                                
                                
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q3 2019 Re...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1944012/0/en/Mersana-Therapeutics-Presents-New-Preclinical-Data-from-Immunosynthen-Platform-at-the-Society-for-Immunotherapy-of-Cancer-SITC-34th-Annual-Meeting.html
                            

                                
Mersana Therapeutics Presents New Preclinical Data from Immunosynthen Platform at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

                                
                                
CAMBRIDGE, Mass., Nov.  08, 2019  (GLOBE NEWSWIRE) -- Mersana Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/27/1921788/0/en/Mersana-Therapeutics-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference.html
                            

                                
Mersana Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

                                
                                
CAMBRIDGE, Mass., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Mersana Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/28/1907687/0/en/Mersana-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html
                            

                                
Mersana Therapeutics to Present at Upcoming Investor Conferences

                                
                                
CAMBRIDGE, Mass., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Mersana Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/20/1904110/0/en/Mersana-Therapeutics-Announces-Initiation-of-Expansion-Study-of-XMT-1536-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-and-Non-Small-Cell-Lung-Cancer.html
                            

                                
Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung Cancer

                                
                                
CAMBRIDGE, Mass., Aug.  20, 2019  (GLOBE NEWSWIRE) -- Mersana Thera...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4284373-mersana-therapeutics-inc-mrsn-ceo-anna-protopapas-q2-2019-results-earnings-call-transcript?source=feed_sector_transcripts
                            

                                
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript

                                
                                
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Re...


                            

                        
                    

                


                            

                    


                        
                            https://247wallst.com/healthcare-business/2019/06/06/5-asco-winners-that-could-still-more-than-double/
                            

                                
ASCO Winners That Could Still More Than Double

                                
                                
The 55th annual meeting of the American Society of Clinical Oncolog...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4266171-mersana-therapeutics-adc-specialist-pursuing-novel-target?source=feed_tag_long_ideas
                            

                                
Mersana Therapeutics: ADC Specialist Pursuing A Novel Target

                                
                                
Shares have lost two-thirds of their value since IPO was priced in ...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4263124-mersana-therapeutics-inc-mrsn-ceo-anna-protopapas-q1-2019-results-earnings-call-transcript?source=feed_sector_transcripts
                            

                                
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2019 Results - Earnings Call Transcript

                                
                                
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2019 Re...


                            

                        
                    

                


                            

                    


                        
                            http://feeds.benzinga.com/~r/benzinga/~3/-v3ZvGhw0YI/jpmorgan-downgrades-mersana-says-data-readouts-unlikely
                            

                                
JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment

                                
                                
Mersana Therapeutics Inc shares, which went public in March 2018, w...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.